

2018

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal G, Bunn P, Chaft J, McCoach C, Perez E, Scagliotti G, *et al*  
*J Thorac Oncol* 2018 Dec;13(12):1818-1831

Phenocopies in melanoma-prone families with germ-line CDKN2A mutations.

Helgadóttir H, Olsson H, Tucker M, Yang X, Höiom V, Goldstein A  
*Genet. Med.* 2018 09;20(9):1087-1090

Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation.

Visnes T, Cázares-Körner A, Hao W, Wallner O, Masuyer G, Loseva O, *et al*  
*Science* 2018 11;362(6416):834-839

Quality of Life After Open Radical Prostatectomy Compared with Robot-assisted Radical Prostatectomy.

Wallerstedt A, Nyberg T, Carlsson S, Thorsteinsdóttir T, Stranne J, Tyrirtis S, *et al*  
*Eur Urol Focus* 2018 Jan;():

Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up.

Rajan P, Hagman A, Sooriakumaran P, Nyberg T, Wallerstedt A, Adding C, *et al*  
*Eur Urol Focus* 2018 04;4(3):351-359

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow-up of the Swedish compassionate use cohort.

Winqvist M, Andersson P, Asklid A, Karlsson K, Karlsson C, Lauri B, *et al*  
*Haematologica* 2018 Dec;():

MutT homologue 1 (MTH1) catalyzes the hydrolysis of mutagenic O6-methyl-dGTP.

Jemth A, Gustafsson R, Bräutigam L, Henriksson L, Vallin K, Sarno A, *et al*  
*Nucleic Acids Res.* 2018 Nov;46(20):10888-10904

The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing.

Eklund M, Nordström T, Aly M, Adolfsson J, Wiklund P, Brandberg Y, *et al*  
*Eur Urol Focus* 2018 09;4(5):707-710

Carboplatin in the neoadjuvant treatment of triple-negative breast cancer-ready for prime time?

Foukakis T  
*Ann. Oncol.* 2018 Dec;29(12):2278-2280

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Fraser G, Cramer P, Demirkan F, Silva R, Grosicki S, Pristupa A, *et al*  
*Leukemia* 2019 Apr;33(4):969-980

Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing.

Bartoschek M, Oskolkov N, Bocci M, Lövrot J, Larsson C, Sommarin M, *et al*  
*Nat Commun* 2018 12;9(1):5150

Discovery of coding regions in the human genome by integrated proteogenomics analysis workflow.

Zhu Y, Orre L, Johansson H, Huss M, Boekel J, Vesterlund M, *et al*  
*Nat Commun* 2018 03;9(1):903

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Cardoso F, Bartlett J, Slaets L, van Deurzen C, van Leeuwen-Stok E, Porter P, *et al*  
*Ann. Oncol.* 2018 02;29(2):405-417

Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups.

Archer T, Ehrenberger T, Mundt F, Gold M, Krug K, Mah C, *et al*  
*Cancer Cell* 2018 Sep;34(3):396-410.e8

The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.

Ström P, Nordström T, Aly M, Egevad L, Grönberg H, Eklund M  
*Eur. Urol.* 2018 08;74(2):204-210

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.

Mayrhofer M, De Laere B, Whittington T, Van Oyen P, Ghysel C, Ampe J, *et al*  
*Genome Med* 2018 11;10(1):85

Implant Based Breast Reconstruction With Acellular Dermal Matrix: Safety Data From an Open-label, Multicenter, Randomized, Controlled Trial in the Setting of Breast Cancer Treatment.

Lohmander F, Lagergren J, Roy P, Johansson H, Brandberg Y, Eriksen C, *et al*  
*Ann. Surg.* 2018 Oct;():

Ribociclib in premenopausal women with advanced breast cancer.

Foukakis T  
*Lancet Oncol.* 2018 07;19(7):850-852

First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.

Sylvan S, Askliid A, Johansson H, Klintman J, Bjellvi J, Tolvgård S, *et al*  
*Haematologica* 2019 Apr;104(4):797-804

Metal-free ribonucleotide reduction powered by a DOPA radical in *Mycoplasma* pathogens.

Srinivas V, Lebrette H, Lundin D, Kutin Y, Sahlin M, Lerche M, *et al*  
*Nature* 2018 11;563(7731):416-420

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.

Rassidakis G, Herold N, Myrberg I, Tsesmetzis N, Rudd S, Henter J, *et al*  
*Blood Cancer J* 2018 Oct;8(11):98

Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy.

Stafford W, Peng X, Olofsson M, Zhang X, Luci D, Lu L, *et al*  
*Sci Transl Med* 2018 Feb;10(428):

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, *et al*  
*Ann. Oncol.* 2018 Aug;29(8):1634-1657

PD-L1 tumor-associated macrophages and PD-1 tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.

Pollari M, Brück O, Pellinen T, Vähämurto P, Karjalainen-Lindsberg M, Mannisto S, *et al*  
*Haematologica* 2018 Nov;103(11):1908-1914

An orthotopic glioblastoma animal model suitable for high-throughput screenings.

Pudelko L, Edwards S, Balan M, Nyqvist D, Al-Saadi J, Dittmer J, *et al*  
*Neuro-oncology* 2018 Oct;20(11):1475-1484

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Pagès F, Mlecnik B, Marliot F, Bindea G, Ou F, Bifulco C, *et al*  
*Lancet* 2018 05;391(10135):2128-2139

A coding and non-coding transcriptomic perspective on the genomics of human metabolic disease.

Timmons J, Atherton P, Larsson O, Sood S, Blokhin I, Brogan R, *et al*  
*Nucleic Acids Res.* 2018 Sep;46(15):7772-7792

Novel Multiomics Profiling of Human Carotid Atherosclerotic Plaques and Plasma Reveals Biliverdin Reductase B as a Marker of Intraplaque Hemorrhage.

Matic L, Jesus Iglesias M, Vesterlund M, Lengquist M, Hong M, Saieed S, *et al*  
*JACC Basic Transl Sci* 2018 Aug;3(4):464-480

Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.

Lodé L, Ménard A, Flet L, Richebourg S, Loirat M, Eveillard M, *et al*  
*Haematologica* 2018 04;103(4):e143-e146

Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations.

Lodé L, Ameur A, Coste T, Ménard A, Richebourg S, Gaillard J, *et al*  
*Haematologica* 2018 01;103(1):e13-e16

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.

Brück O, Blom S, Dufva O, Turkki R, Chheda H, Ribeiro A, *et al*  
*Leukemia* 2018 07;32(7):1643-1656

Reduced Expression of PROX1 Transitions Glioblastoma Cells into a Mesenchymal Gene Expression Subtype.

Goudarzi K, Espinoza J, Guo M, Bartek J, Nistér M, Lindström M, *et al*  
*Cancer Res.* 2018 Oct;78(20):5901-5916

Modulation of Protein-Interaction States through the Cell Cycle.

Dai L, Zhao T, Bisteau X, Sun W, Prabhu N, Lim Y, *et al*  
*Cell* 2018 05;173(6):1481-1494.e13

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.

Malcikova J, Tausch E, Rossi D, Sutton L, Soussi T, Zenz T, *et al*  
*Leukemia* 2018 05;32(5):1070-1080

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein H, Winer E, Gnant M, Dubsy P, Loibl S, *et al*  
*Ann. Oncol.* 2018 Oct;29(10):2153

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.

Azimi A, Caramuta S, Seashore-Ludlow B, Boström J, Robinson J, Edfors F, *et al*  
*Mol. Syst. Biol.* 2018 03;14(3):e7858

Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.

Björklund A, Carlsten M, Sohlberg E, Liu L, Clancy T, Karimi M, *et al*  
*Clin. Cancer Res.* 2018 Apr;24(8):1834-1844

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, *et al*  
*Ann. Oncol.* 2018 Oct;29(Supplement\_4):iv96-iv110

Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.

Mundt F, Rajput S, Li S, Ruggles K, Mooradian A, Mertins P, *et al*  
*Cancer Res.* 2018 May;78(10):2732-2746

Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy.

Stafford W, Peng X, Olofsson M, Zhang X, Luci D, Lu L, *et al*  
*Sci Transl Med* 2018 Feb;10(428):

Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells.

Page B, Valerie N, Wright R, Wallner O, Isaksson R, Carter M, *et al*  
*Nat Commun* 2018 01;9(1):250

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.

Cats A, Jansen E, van Grieken N, Sikorska K, Lind P, Nordmark M, *et al*  
*Lancet Oncol.* 2018 05;19(5):616-628

First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.

Hojjat-Farsangi M, Daneshmanesh A, Khan A, Shetye J, Mozaffari F, Kharaziha P, *et al*  
*Leukemia* 2018 Oct;32(10):2291-2295

Integrated multi-omic analysis of host-microbiota interactions in acute oak decline.

Broberg M, Doonan J, Mundt F, Denman S, McDonald J  
*Microbiome* 2018 01;6(1):21

Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.

Ren W, Ye X, Su H, Li W, Liu D, Pirmoradian M, *et al*  
*Blood* 2018 Jun;131(24):2670-2681

Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations.

Shah M, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, *et al*  
*Genome Res.* 2018 04;28(4):432-447

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson S, Abrams J, Adam D, Agostinis P, *et al*  
*Cell Death Differ.* 2018 Mar;25(3):486-541

Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.

Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, *et al*  
*Cell* 2018 05;173(4):879-893.e13

Circadian organization of the genome.

Mallet de Lima C, Göndör A  
*Science* 2018 03;359(6381):1212-1213

Goserelin does not preserve ovarian function against chemotherapy-induced damage.

Oktay K, Taylan E, Rodriguez-Wallberg K, Bedoschi G, Turan V, Pacheco F  
*Ann. Oncol.* 2018 02;29(2):512-513

Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.

Sveen A, Bruun J, Eide P, Eilertsen I, Ramirez L, Murumägi A, *et al*  
*Clin. Cancer Res.* 2018 Feb;24(4):794-806

Discovery of coding regions in the human genome by integrated proteogenomics analysis workflow.

Zhu Y, Orre L, Johansson H, Huss M, Boekel J, Vesterlund M, *et al*  
*Nat Commun* 2018 03;9(1):903

Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach.

Bereczki E, Branca R, Francis P, Pereira J, Baek J, Hortobágyi T, *et al*  
*Brain* 2018 Feb;141(2):582-595

A Common Peptidolytic Mechanism for Targeting Peptide Degradation in Mitochondria and Chloroplasts.

Kmiec B, Branca R, Murcha M, Lehtiö J, Glaser E, Teixeira P  
*Mol Plant* 2018 02;11(2):342-345

Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes.

Ullah I, Karthik G, Alkodsai A, Kjällquist U, Stålhammar G, Lövrot J, *et al*  
*J. Clin. Invest.* 2018 Apr;128(4):1355-1370

Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial.

Sooriakumaran P, Pini G, Nyberg T, Derogar M, Carlsson S, Stranne J, *et al*  
*Eur. Urol.* 2018 04;73(4):618-627

Driving Protein Conformational Changes with Light: Photoinduced Structural Rearrangement in a Heterobimetallic Oxidase.

Maugeri P, Griese J, Branca R, Miller E, Smith Z, Eirich J, *et al*  
*J. Am. Chem. Soc.* 2018 01;140(4):1471-1480

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Andersson E, Pützer S, Yadav B, Dufva O, Khan S, He L, *et al*  
*Leukemia* 2018 03;32(3):774-787

MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling.

Dzieran J, Rodriguez Garcia A, Westermark U, Henley A, Eyre Sánchez E, Träger C, *et al*  
*Proc. Natl. Acad. Sci. U.S.A.* 2018 02;115(6):E1229-E1238

Targeting mutant p53 for efficient cancer therapy.

Bykov V, Eriksson S, Bianchi J, Wiman K  
*Nat. Rev. Cancer* 2018 Feb;18(2):89-102

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.

*Lancet Oncol.* 2018 01;19(1):27-39

Polysome-profiling in small tissue samples.

Liang S, Bellato H, Lorent J, Lupinacci F, Oertlin C, van Hoef V, *et al*  
*Nucleic Acids Res.* 2018 Jan;46(1):e3

Risk of Acute Testicular Failure After Preoperative Radiotherapy for Rectal Cancer: A Prospective Cohort Study.

Buchli C, Martling A, Abani M, Frödin J, Bottai M, Lax I, *et al*  
*Ann. Surg.* 2018 02;267(2):326-331